-       Report 
   - July 2024
    -  326 Pages 
    China
   
   From       €3595EUR$4,000USD£3,153GBP 
                -       Report 
   - July 2024
    -  90 Pages 
    China
   
   From       €1618EUR$1,800USD£1,419GBP 
                -       Report 
   - September 2025
    -  87 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                -       Report 
   - August 2025
    -  105 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                -       Report 
   - November 2024
    -  104 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                 -       Report 
   - October 2024
    -  85 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                -       Report 
   - October 2023
    -  92 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                -       Report 
   - November 2024
    -  86 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                    -       Report 
   - November 2024
    -  90 Pages 
    Australia
   
   From       €1671EUR$1,859USD£1,465GBP 
                                -       Book 
   - October 2012
    -  1570 Pages 
    
          
         The Vaccine Adjuvant market is a subset of the Vaccines market, which is composed of products that are used to enhance the effectiveness of vaccines. Vaccine adjuvants are substances that are added to vaccines to increase the body's immune response to the vaccine. Adjuvants can be either natural or synthetic, and can be used to increase the potency of a vaccine, reduce the amount of antigen needed, or to extend the duration of the vaccine's effectiveness. Vaccine adjuvants are used in a variety of    vaccines, including those for influenza, hepatitis, and human papillomavirus.
Some companies in the Vaccine Adjuvant market include GlaxoSmithKline, Merck, Sanofi, and Novartis. Show Less   Read more